RCS - Ondine Biomedical - Steriwave in British Columbia Health Authorities

Ondine BiomedicalAnnouncement

23/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240823:nRSW5065Ba&default-theme=true

RNS Number : 5065B  Ondine Biomedical Inc.  23 August 2024

ONDINE BIOMEDICAL INC.

 

("Ondine Biomedical", "Ondine" or the "Company")

 

Steriwave in all British Columbia Health Authorities

 

Ondine Biomedical Inc. (LON: OBI), a leading provider of light-activated
antimicrobial technology to prevent and treat hospital infections, is pleased
to announce that Steriwave® nasal decolonization is now being used in all
five of British Columbia's health authorities. This deployment signals
Ondine's increasingly strong presence across the Canadian healthcare system.

 

As of 21 August 2024, the University Hospital of Northern British Columbia
(UHNBC) in Prince George, a major hub for specialized surgical care in
Northern BC, has begun using Steriwave to treat patients undergoing hip and
knee arthroplasties. With this deployment at UHNBC, Steriwave is now
operational in all five of British Columbia's health authorities: Vancouver
Coastal Health, Fraser Health, Vancouver Island Health, Interior Health, and
Northern Health.

Carolyn Cross, CEO of Ondine Biomedical, commented:

"Our mission is to bring our non-resistance-forming photodisinfection
technology into hospitals to safeguard patients and healthcare workers from
the growing threat of multidrug resistance and other emerging health
challenges. Steriwave, a simple five-minute treatment that removes nasal
pathogens-the source of many hospital-acquired infections-plays a crucial role
in this effort. The adoption of Steriwave by the largest hospital in northern
British Columbia is a significant achievement for Ondine. We are proud to be
working with all of BC's health authorities to avoid infections and their
associated human and financial costs."

Canadian hospitals using Steriwave have reported reduced surgical site
infections, decreased antibiotic use, shorter hospital stays, lower mortality
rates, fewer respiratory infections, significant cost savings, with high
levels of compliance and patient and clinician satisfaction.

Steriwave nasal photodisinfection is a non-invasive, light-activated
antimicrobial treatment that has been clinically proven to reduce pathogens in
the nasal passages, thereby lowering the risk of hospital-acquired infections.
Steriwave's rapid action prevents pathogens from developing resistance,
offering an effective alternative to antibiotics. A 2023 study showed that
Steriwave is highly effective (>99.99% kills in 20 seconds) against both
moderately drug-resistant (MDR) and extensively drug-resistant (XDR)
pathogens.

 

Enquiries:

 

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                                           +001 (604) 665 0555

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Phil Davies, Sam Butcher                                     +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                             +44 (0)77 1000 5910

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a clinical Canadian life sciences company and leader
in light-activated antimicrobial therapies (also known as
'photodisinfection'). Ondine has a pipeline of investigational products, based
on its proprietary photodisinfection technology, in various stages of
development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and
is approved in Canada and several other countries under the name
Steriwave(®). In the US, it has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

About Steriwave(®)

Ondine's Steriwave nasal photodisinfection system is a patented technology
using a proprietary light-activated antimicrobial (photosensitizer) to destroy
bacteria, viruses, and fungi colonizing the nose. The photodisinfection
treatment is carried out by a trained healthcare professional and is an
easy-to-use, painless, two-step process. The photosensitizer is applied to
each nostril using a nasal swab, followed by illumination of the area with a
specific wavelength of red laser light for less than five minutes. The light
activates the photosensitizer, causing an oxidative burst that is lethal to
all types of pathogens without causing long-term adverse effects on the nasal
microbiome. A key benefit of this approach-unlike with antibiotics, which have
resistance rates reported as high as 81% 1 -is that pathogens do not develop
resistance to the therapy.

 

Nasal decolonization is recommended in the 2016 WHO Global guidelines for the
prevention of surgical site infections, 2  and the Society for Healthcare
Epidemiology of America (SHEA) guidelines, published in May 2023, recommend
nasal decolonization for major surgical procedures. 3 

 

 

 

 1  Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical
implications and potential alternatives for the eradication of MRSA. J
Antimicrob Chemother. 2015;70(10):2681-2692. (link
(https://academic.oup.com/jac/article/70/10/2681/829798?login=false) )

 2  Surgical Site Infection Prevention: Key facts on decolonization of nasal
carriers of Staphylococcus aureus. World Health Organization. (link
(https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2)
)

 3  Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent
surgical site infections in acute-care hospitals: 2022 Update. Infect Control
Hosp Epidemiol. 2023;44(5):695-720. (link
(https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/strategies-to-prevent-surgical-site-infections-in-acutecare-hospitals-2022-update/2F824B9ADD6066B29F89C8A2A127A9DC)
)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRALLLLLZVLLBBF